REVIEW

Oxidative stress and redox signalling in cardiac hypertrophy and heart failure

Mike Seddon, Yee H Looi, Ajay M Shah

Department of Cardiology, King’s College London, Cardiovascular Division, London, UK

Correspondence to:
Professor A M Shah
Department of Cardiology, King’s College London School of Medicine, Bessemer Road, London SE5 9PJ, UK;ajay.shah{at}kcl.ac.uk

Substantial evidence suggests the involvement of oxidative stress in the pathophysiology of congestive heart failure and its antecedent conditions such as cardiac hypertrophy and adverse remodelling after MI. Oxidative stress describes an imbalance between antioxidant defences and the production of reactive oxygen species (ROS), which at high levels cause cell damage but at lower levels induce subtle changes in intracellular signalling pathways (termed redox signalling). ROS are derived from many sources including mitochondria, xanthine oxidase, uncoupled nitric oxide synthases and NADPH oxidases. The latter enzymes are especially important in redox signalling, being implicated in the pathophysiology of hypertension and atherosclerosis, and activated by diverse pathologically relevant stimuli. We review the contribution of ROS to heart failure pathophysiology and discuss potential therapies that may specifically target detrimental redox signalling. Indeed, drugs such as ACE inhibitors and statins may act in part through such mechanisms. A better understanding of redox signalling mechanisms may enable the development of new targeted therapeutic strategies rather than the non-specific antioxidant approaches that have to date been disappointing in clinical trials.

Abbreviations: CHF, congestive heart failure; LVH, left ventricular hypertrophy; ROS, reactive oxygen species

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Bergamini, C., Cicoira, M., Rossi, A., Vassanelli, C. (2009). Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 11: 444-452 [Abstract] [Full Text]  
• Singh, S., Manda, S. M., Sikder, D., Birrer, M. J., Rothermel, B. A., Garry, D. J., Mammen, P. P. A. (2009). Calcineurin Activates Cytoglobin Transcription in Hypoxic Myocytes. J. Biol. Chem. 284: 10409-10421 [Abstract] [Full Text]  
• Heymans, S., Hirsch, E., Anker, S. D., Aukrust, P., Balligand, J.-L., Cohen-Tervaert, J. W., Drexler, H., Filippatos, G., Felix, S. B., Gullestad, L., Hilfiker-Kleiner, D., Janssens, S., Latini, R., Neubauer, G., Paulus, W. J., Pieske, B., Ponikowski, P., Schroen, B., Schultheiss, H.-P., Tschope, C., Van Bilsen, M., Zannad, F., McMurray, J., Shah, A. M. (2009). Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 11: 119-129 [Abstract] [Full Text]  
• Rietzschel, E. R., Langlois, M., De Buyzere, M. L., Segers, P., De Bacquer, D., Bekaert, S., Cooman, L., Van Oostveldt, P., Verdonck, P., De Backer, G. G., Gillebert, T. C., for the Asklepios Investigators, (2008). Oxidized Low-Density Lipoprotein Cholesterol Is Associated With Decreases in Cardiac Function Independent of Vascular Alterations. Hypertension 52: 535-541 [Abstract] [Full Text]  
• Jacques, A. M., Briceno, N., Messer, A. E., Gallon, C. E., Jalilzadeh, S., Garcia, E., Kikonda-Kanda, G., Goddard, J., Harding, S. E., Watkins, H., Esteban, M. T., Tsang, V. T., McKenna, W. J., Marston, S. B. (2008). The molecular phenotype of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy. Cardiovasc Res 79: 481-491 [Abstract] [Full Text]